The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and baseline characteristics ⁎ ⁎ Roy W. Jones and Miia Kivipelto contributed equally to the content of the manuscript.

[1]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[2]  J. Dichgans,et al.  Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26‐week randomized, placebo‐controlled, double‐blind trial , 2002, Annals of neurology.

[3]  D. Sparks,et al.  Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease , 1990, Neurobiology of Aging.

[4]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[5]  K. Blennow,et al.  Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. , 2003, Dementia and geriatric cognitive disorders.

[6]  I. Björkhem,et al.  Oxysterols and Alzheimer's disease , 2006, Acta neurologica Scandinavica. Supplementum.

[7]  S H Ferris,et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.

[8]  M. Hennerici,et al.  Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[10]  J. Adair,et al.  Cholesterol and neuropathologic markers of AD , 2001, Neurology.

[11]  J. Hey-Hadavi,et al.  Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials. , 2006, The American journal of geriatric pharmacotherapy.

[12]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[13]  S. Yudofsky,et al.  Association of Serum Cholesterol and Triglyceride Levels with Agitation and Cognitive Function in a Geropsychiatry Unit , 1996, Journal of geriatric psychiatry and neurology.

[14]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[15]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[16]  Dr Robert Bryant,et al.  Re‐assessing the relationship between cholesterol, statins and Alzheimer's disease , 2006, Acta neurologica Scandinavica. Supplementum.

[17]  K Yaffe,et al.  Midlife cardiovascular risk factors and risk of dementia in late life , 2005, Neurology.

[18]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[19]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[20]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[21]  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[22]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Schweiger.  [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[24]  Lewis E Kazis,et al.  Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease , 2007, BMC medicine.

[25]  Qian-Li Xue,et al.  Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. , 2007, Archives of neurology.

[26]  H. Soininen,et al.  Serum cholesterol changes after midlife and late-life cognition , 2007, Neurology.

[27]  K. Rockwood,et al.  Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease , 2006, Acta neurologica Scandinavica. Supplementum.

[28]  B. Austen,et al.  Cholesterol upregulates production of Aβ 1–40 and 1–42 in transfected cells , 2000, Neurobiology of Aging.

[29]  Hilkka Soininen,et al.  Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. , 2005, Archives of neurology.

[30]  J. Mckenney,et al.  Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. , 2005, American heart journal.

[31]  C. Dessy,et al.  Hydroxy-Methylglutaryl–Coenzyme A Reductase Inhibition Promotes Endothelial Nitric Oxide Synthase Activation Through a Decrease in Caveolin Abundance , 2001, Circulation.

[32]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[33]  K. Blennow,et al.  The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.

[34]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[35]  A. Arshad,et al.  STATINS, INCIDENT ALZHEIMER DISEASE, CHANGE IN COGNITIVE FUNCTION, AND NEUROPATHOLOGY , 2008, Neurology.

[36]  E. Barrett-Connor,et al.  Serum lipoprotein levels, statin use, and cognitive function in older women. , 2002, Archives of neurology.

[37]  P. Mcgeer,et al.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain , 2001, Neuroreport.

[38]  S. Fichtlscherer,et al.  Increase in Circulating Endothelial Progenitor Cells by Statin Therapy in Patients With Stable Coronary Artery Disease , 2001, Circulation.

[39]  B. Strooper,et al.  Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[41]  Patrick Browne,et al.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. , 2005, Archives of neurology.

[42]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[43]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[44]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[45]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[46]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[47]  K. Blennow,et al.  Treatment with Simvastatin in Patients with Alzheimer’s Disease Lowers Both α- and β-Cleaved Amyloid Precursor Protein , 2003, Dementia and Geriatric Cognitive Disorders.

[48]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[49]  B. Winblad,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.

[50]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[51]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[52]  B. Winblad,et al.  3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy , 2006, Dementia and Geriatric Cognitive Disorders.

[53]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[54]  R. Michels,et al.  Diagnostic and Statistical Manual of Mental Disorders, 3rd ed , 1981 .

[55]  L. Thal,et al.  Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology , 2003, Neurology.

[56]  Lewis H Kuller,et al.  Statin use and the risk of incident dementia: the Cardiovascular Health Study. , 2005, Archives of neurology.

[57]  P. Libby,et al.  High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study , 2003, Circulation.

[58]  D L Sparks,et al.  Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol‐Lowering Treatment (ADCLT) trial , 2006, Acta neurologica Scandinavica. Supplementum.